Needham analyst Ryan MacDonald downgrades Momentive Glb (NASDAQ:MNTV) from Buy to Hold.
Inozyme Pharma Announces Dosing Of First Infant With ENPP1 Deficiency In A Phase 1b Trial Of INZ-701
Inozyme Pharma, Inc. (NASDAQ:INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today